Internal Medicine, Rheumatology · Longview, TX
NPI
1013912856
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
920 Judson Rd
Longview, TX, 75601
Phone (903) 236-7020
Groups this clinician bills Medicare through
Medicare paid, 2024
$502K
32,533 services
Medicare patients, 2024
611
Average age 71
Drug cost, 2024
$9.4M
17,518 prescriptions
Company payments, 2025
$5,288
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kayvan Kamali was code J0897 (injection, denosumab, 1 mg), 3,720 times for 40 patients. In total Kayvan Kamali billed 32,533 services in 30 codes, and Medicare paid $502K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-12-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 3,720 | 40 | $20.62 | $77K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 2,176 | 33 | $0.11 | $231 |
| 99214 Office E&M - Established | Office | 1,500 | 519 | $82.67 | $124K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 356 | 61 | $0.68 | $241 |
| 99213 Office E&M - Established | Office | 212 | 122 | $58.41 | $12K |
| 77080 Standard X-ray | Office | 207 | 207 | $36.07 | $7,467 |
| 96372 Injection Administration | Office | 190 | 112 | $9.71 | $1,844 |
| 96413 Chemotherapy Administration | Office | 84 | 15 | $93.63 | $7,865 |
| 72082 X-ray - Spine and Pelvis | Office | 81 | 81 | $45.39 | $3,677 |
| 99205 Office E&M - New | Office | 79 | 79 | $141.18 | $11K |
| 73221 MRI/MRA - Other | Office | 46 | 45 | $84.15 | $3,871 |
| 73218 MRI/MRA - Other | Office | 42 | 42 | $172.40 | $7,241 |
| 20610 Joint Injection | Office | 37 | 30 | $54.10 | $2,002 |
| 20550 Musculoskeletal | Office | 17 | 12 | $34.92 | $594 |
By year: 2022 $546K for 26,924 services; 2023 $475K for 26,693 services; 2024 $502K for 32,533 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kayvan Kamali prescribed most often to Medicare patients was Tramadol Hcl, with 2,432 prescriptions and refills. In total Kayvan Kamali wrote 17,518 Medicare prescriptions that cost $9.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tramadol Hcl Generic | 2,432 | 2,433 | 509 | $25K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 1,776 | 1,776 | 217 | $57K |
| Methotrexate Methotrexate Sodium | 1,155 | 1,909 | 330 | $20K |
| Pregabalin Generic | 1,040 | 1,376 | 195 | $22K |
| Sulfasalazine Generic | 900 | 1,425 | 245 | $23K |
| Hydroxychloroquine Sulfate Generic | 821 | 1,426 | 210 | $23K |
| Gabapentin Generic | 772 | 1,142 | 198 | $10K |
| Duloxetine Hcl Generic | 764 | 1,224 | 181 | $14K |
| Oxycodone Hcl Generic | 696 | 696 | 97 | $12K |
| Acetaminophen-Codeine Acetaminophen With Codeine | 633 | 636 | 120 | $20K |
| Tizanidine Hcl Generic | 573 | 753 | 169 | $8,161 |
| Humira(Cf) Pen Adalimumab | 495 | 496 | 69 | $3.4M |
| Leflunomide Generic | 486 | 853 | 127 | $19K |
| Prednisone Generic | 469 | 518 | 258 | $2,244 |
| Alendronate Sodium Generic | 410 | 695 | 112 | $2,115 |
Brand drugs: - claims; generic drugs: 15,097 claims; opioid claims: 6,378.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kayvan Kamali $5,288 ($5,288 in general payments such as food, travel and fees) from 20 companies. The largest payer was Abbvie Inc. with $1,833.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 71 | $1,833 |
| Amgen Inc. AMGN | 36 | $711 |
| Janssen Biotech, Inc. JNJ | 19 | $629 |
| UCB, Inc. UCB.BR | 10 | $350 |
| Novartis Pharmaceuticals Corporation NVS | 12 | $282 |
| AstraZeneca Pharmaceuticals LP AZN | 6 | $214 |
| GlaxoSmithKline, LLC. GSK | 12 | $208 |
| Lilly USA, LLC LLY | 9 | $169 |
| Genzyme Corporation SNY | 5 | $166 |
| Collegium Pharmaceutical, Inc. COLL | 7 | $134 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.